BioRestorative Stock Surges After Recruiting PRC Clinical As Partner For Lead Product Study

BioRestorative Therapies Inc BRTX has entered into a Master Service Agreement with PRC Clinical, a contract research organization (CRO), to conduct BioRestorative's Phase 2 trial.

  • According to the agreement, PRC Clinical will manage BioRestorative's Phase 2 clinical study of BRTX-100, the Company's lead clinical product to treat chronic lumbar disc disease.
  • The Company's lead cell therapy candidate, BRTX-100, is a product formulated from autologous (or a person's own) cultured mesenchymal stem cells collected from the patient's bone marrow. 
  • BioRestorative plans to develop the product for the non-surgical treatment of lumbosacral disc disorders or as a complementary therapeutic to a surgical procedure. 
  • In an outpatient procedure, one-time BRTX-100 will be injected with 40 million mesenchymal stem cells into the patient's damaged disc by a physician.
  • In November of this year, BioRestorative closed on a $23 million capital raise and concurrently listed on the Nasdaq Capital Market. 
  • The Company says it is fully funded to complete the Phase 2 trial for BRTX-100 for chronic lumbar disc disease.
  • Price Action: BRTX shares are up 56.9% at $7.17 during the premarket session on the last check Wednesday.
Loading...
Loading...
BRTX Logo
BRTXBioRestorative Therapies Inc
$1.59-1.24%

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score
Edge Rankings
Momentum
28.70
Growth
Not Available
Quality
Not Available
Value
14.45
Price Trend
Short
Medium
Long
Market News and Data brought to you by Benzinga APIs

Comments
Loading...